Phaseline

Companies › Bliss Biopharmaceutical (Hangzhou)

Bliss Biopharmaceutical (Hangzhou): clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BB-1709–Phase 1Solid TumorDec 2026
BB-1705
Antibody-drug conjugate with humanized IgG1κ monoclonal antibody conjugated to eribulin vi
–Phase 1Solid Tumor–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05217693BB-1705Phase 1Solid TumorOncologyJun 2025
NCT06241898BB-1709Phase 1Solid TumorOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.